Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.
Journal
Obesity (Silver Spring, Md.)
ISSN: 1930-739X
Titre abrégé: Obesity (Silver Spring)
Pays: United States
ID NLM: 101264860
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
13
09
2022
received:
26
07
2022
accepted:
28
09
2022
pubmed:
12
12
2022
medline:
23
12
2022
entrez:
11
12
2022
Statut:
ppublish
Résumé
This paper describes the baseline characteristics of the Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the largest cardiovascular (CV) outcome studies in the field of obesity, which evaluates the effect of semaglutide versus placebo on major CV events. SELECT enrolled individuals with overweight or obesity without diabetes, with prior myocardial infarction, stroke, and/or peripheral artery disease. This study reports participants' baseline characteristics in the full study population and subgroups defined by baseline glycated hemoglobin (HbA The study enrolled 17,605 participants (72.5% male) with an average (SD) age of 61.6 (8.9) years and BMI of 33.34 (5.04) kg/m The enrolled population in SELECT includes participants across a broad range of relevant risk categories. This will allow the study to garner information about the CV benefits of semaglutide across these relevant clinical subgroups.
Identifiants
pubmed: 36502289
doi: 10.1002/oby.23621
pmc: PMC10107832
doi:
Substances chimiques
Hypoglycemic Agents
0
semaglutide
53AXN4NNHX
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
111-122Informations de copyright
© 2022 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society.
Références
Mol Metab. 2021 Apr;46:101102
pubmed: 33068776
N Engl J Med. 2019 Aug 29;381(9):841-851
pubmed: 31185157
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
Circulation. 2021 May 25;143(21):e984-e1010
pubmed: 33882682
Cardiovasc Diabetol. 2021 Sep 15;20(1):189
pubmed: 34526024
N Engl J Med. 2018 Sep 20;379(12):1107-1117
pubmed: 30145941
Lancet. 2010 Aug 14;376(9740):517-23
pubmed: 20709233
N Engl J Med. 2013 Jul 11;369(2):145-54
pubmed: 23796131
JAMA. 2021 Apr 13;325(14):1414-1425
pubmed: 33755728
Lancet Diabetes Endocrinol. 2019 Sep;7(9):715-725
pubmed: 31301983
Lancet. 2021 Mar 13;397(10278):971-984
pubmed: 33667417
N Engl J Med. 2021 Mar 18;384(11):989-1002
pubmed: 33567185
JAMA. 2022 Jan 11;327(2):138-150
pubmed: 35015037
JAMA. 2021 Apr 13;325(14):1403-1413
pubmed: 33625476
Lancet Diabetes Endocrinol. 2016 Nov;4(11):913-921
pubmed: 27595918
Am Heart J. 2020 Nov;229:61-69
pubmed: 32916609
Lancet Diabetes Endocrinol. 2022 Mar;10(3):193-206
pubmed: 35131037
Surg Obes Relat Dis. 2022 Aug;18(8):1074-1086
pubmed: 35717432
N Engl J Med. 2010 Sep 2;363(10):905-17
pubmed: 20818901
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
JAMA. 2016 Mar 8;315(10):990-1004
pubmed: 26954408
Diabetes Care. 2009 Jul;32(7):1327-34
pubmed: 19502545
Obesity (Silver Spring). 2023 Jan;31(1):111-122
pubmed: 36502289
Circulation. 2020 Sep 22;142(12):1205-1218
pubmed: 32955939
Nutr Res Rev. 2010 Dec;23(2):247-69
pubmed: 20819243
Circulation. 2019 Jun 18;139(25):e1046-e1081
pubmed: 30565953